Patents by Inventor David A. Kummer

David A. Kummer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11897900
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: February 13, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • Publication number: 20230176617
    Abstract: A mobile device includes a first display portion, a second display portion and a graphics processor. The first display portion is viewable while the second display portion is obscured when the mobile device is in a retracted configuration. Both display portions are viewable when the mobile device is in an expanded configuration. The graphics processor may be coupled to each display portion and configured to generate a first image for display on: the first display portion when the mobile device is in the retracted configuration; at least one of the display portions while the mobile device is in the expanded configuration; and at least one of the display portions while the mobile device transitions between the retracted configuration and the expanded configuration. The second display portion may be a flexible display material, such as an OLED display and with the first display portion may be a single sheet OLED display.
    Type: Application
    Filed: July 23, 2022
    Publication date: June 8, 2023
    Applicant: DISH Technologies L.L.C.
    Inventors: David A. Kummer, Danny J. Minnick
  • Publication number: 20220315604
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: December 18, 2020
    Publication date: October 6, 2022
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • Publication number: 20220281823
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: May 5, 2022
    Publication date: September 8, 2022
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Virginia M. Tanis, Craig R. Woods, Anne M. Fourie, Xiaohua Xue
  • Patent number: 11427601
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: August 30, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • Patent number: 11416031
    Abstract: A mobile device includes a first display portion, a second display portion and a graphics processor. The first display portion is viewable while the second display portion is obscured when the mobile device is in a retracted configuration. Both display portions are viewable when the mobile device is in an expanded configuration. The graphics processor may be coupled to each display portion and configured to generate a first image for display on: the first display portion when the mobile device is in the retracted configuration; at least one of the display portions while the mobile device is in the expanded configuration; and at least one of the display portions while the mobile device transitions between the retracted configuration and the expanded configuration. The second display portion may be a flexible display material, such as an OLED display and with the first display portion may be a single sheet OLED display.
    Type: Grant
    Filed: February 7, 2021
    Date of Patent: August 16, 2022
    Assignee: DISH Technologies L.L.C.
    Inventors: David A. Kummer, Danny J. Minnick
  • Patent number: 11345666
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: May 31, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Virginia M. Tanis, Craig R. Woods
  • Publication number: 20210173445
    Abstract: A mobile device includes a first display portion, a second display portion and a graphics processor. The first display portion is viewable while the second display portion is obscured when the mobile device is in a retracted configuration. Both display portions are viewable when the mobile device is in an expanded configuration. The graphics processor may be coupled to each display portion and configured to generate a first image for display on: the first display portion when the mobile device is in the retracted configuration; at least one of the display portions while the mobile device is in the expanded configuration; and at least one of the display portions while the mobile device transitions between the retracted configuration and the expanded configuration. The second display portion may be a flexible display material, such as an OLED display and with the first display portion may be a single sheet OLED display.
    Type: Application
    Filed: February 7, 2021
    Publication date: June 10, 2021
    Applicant: DISH Technologies L.L.C.
    Inventors: David A. Kummer, Danny J. Minnick
  • Patent number: 10975057
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: April 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Anne M. Fourie, Xiaohua Xue
  • Patent number: 10975037
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: April 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Craig R. Woods, Ronald L. Wolin, William M. Jones, Anne M. Fourie, Xiaohua Xue
  • Patent number: 10947252
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: March 16, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • Patent number: 10659837
    Abstract: Content receivers may simultaneously record multiple instances of content for multiple programming channels based on content provider instructions. Systems and methods utilize the content receivers to record these multiple instances from at least a single transponder. In some instances, multiple transponders may have a common control word so that content carried on each such transponder may be simultaneously received, decoded and recorded. Further, a single demodulator may be associated with multiple tuners, so that the single demodulator processes all content received from transponders with common control words and/or other encryption mechanisms.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: May 19, 2020
    Assignee: DISH Technologies L.L.C.
    Inventors: Henry Gregg Martch, David A. Kummer, John T. Kennedy
  • Publication number: 20200055874
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: August 19, 2019
    Publication date: February 20, 2020
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • Patent number: 10555941
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: February 11, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Maxwell D. Cummings
  • Publication number: 20190382354
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 19, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Virginia M. Tanis, Craig R. Woods, Anne M. Fourie, Xiaohua Xue
  • Publication number: 20190382373
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 19, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Anne M. Fourie, Xiaohua Xue
  • Publication number: 20190382349
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 19, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Craig R. Woods, Ronald L. Wolin, William M. Jones, Anne M. Fourie, Xiaohua Xue
  • Publication number: 20190377384
    Abstract: A portable communications device includes a first screen and a second screen. A third screen may be provided. The device includes a housing into in and from which each of the second and/or third screens may be retracted and extended. When retracted, outer edges of the second and/or third screens encase opposing sides of the first screen. A cavity in the housing is provided into which the second and third screens may be retracted. Track mechanisms and bearing mechanisms may support and facilitate extension and retraction of the second and third screens. Spring mechanisms facilitate alignment of the first, second and third screens. Holding and/or cooperative release mechanisms may be used to respectively hold and release the second and third screens within the housing.
    Type: Application
    Filed: July 29, 2019
    Publication date: December 12, 2019
    Applicant: DISH Technologies L.L.C.
    Inventors: David A. Kummer, Danny J. Minnick
  • Patent number: 10477258
    Abstract: A method for creating an announcement stream for a geographic region is provided. The method receives, at a designated computer system, characterizing metadata for a first audio/video stream; analyzes a second audio/video stream to obtain characterizing metadata for the second video stream; compares, with the computer system, the characterizing metadata for the first video stream to the characterizing metadata for the second video stream to generate offset data; and calculates timing information corresponding to segment boundaries for the second video stream using the offset data.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: November 12, 2019
    Assignee: DISH TECHNOLOGIES LLC
    Inventors: David A. Kummer, Steven M. Casagrande
  • Publication number: 20190320215
    Abstract: A method for creating an announcement stream for a geographic region is provided. The method receives, at a designated computer system, characterizing metadata for a first audio/video stream; analyzes a second audio/video stream to obtain characterizing metadata for the second video stream; compares, with the computer system, the characterizing metadata for the first video stream to the characterizing metadata for the second video stream to generate offset data ; and calculates timing information corresponding to segment boundaries for the second video stream using the offset data.
    Type: Application
    Filed: May 3, 2017
    Publication date: October 17, 2019
    Applicant: DISH TECHNOLOGIES LLC
    Inventors: David A. Kummer, Steven M. Casagrande